Michael J. Mcbreen Sells 1,700 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) Stock

Integra LifeSciences Holdings Co. (NASDAQ:IART) EVP Michael J. Mcbreen sold 1,700 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the sale, the executive vice president now directly owns 56,182 shares in the company, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Integra LifeSciences Stock Up 0.2 %

NASDAQ IART traded up $0.05 on Tuesday, hitting $24.63. 347,199 shares of the stock traded hands, compared to its average volume of 1,083,627. Integra LifeSciences Holdings Co. has a twelve month low of $16.81 and a twelve month high of $45.42. The stock has a 50-day moving average of $20.92 and a 200 day moving average of $23.94. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The company has a market capitalization of $1.90 billion, a P/E ratio of -271.19, a price-to-earnings-growth ratio of 0.84 and a beta of 1.15.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. The business had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business’s revenue for the quarter was down .4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.76 EPS. As a group, analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IART has been the subject of several research reports. Citigroup lifted their price target on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Bank of America reduced their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating on the stock in a research note on Monday, October 7th. Morgan Stanley initiated coverage on Integra LifeSciences in a research report on Monday. They set an “underweight” rating and a $20.00 price target on the stock. Finally, Truist Financial dropped their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, Integra LifeSciences has an average rating of “Hold” and an average target price of $23.00.

Institutional Investors Weigh In On Integra LifeSciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Systematic Financial Management LP boosted its holdings in shares of Integra LifeSciences by 53.9% in the third quarter. Systematic Financial Management LP now owns 611,746 shares of the life sciences company’s stock worth $11,115,000 after buying an additional 214,272 shares during the period. Sachem Head Capital Management LP purchased a new stake in shares of Integra LifeSciences during the 3rd quarter worth about $44,153,000. Centiva Capital LP acquired a new stake in Integra LifeSciences in the third quarter valued at approximately $192,000. Clearline Capital LP lifted its stake in shares of Integra LifeSciences by 226.8% in the 3rd quarter. Clearline Capital LP now owns 230,397 shares of the life sciences company’s stock valued at $4,186,000 after purchasing an additional 159,903 shares during the last quarter. Finally, Walleye Capital LLC boosted its stake in shares of Integra LifeSciences by 758.7% during the 3rd quarter. Walleye Capital LLC now owns 234,506 shares of the life sciences company’s stock worth $4,261,000 after acquiring an additional 207,196 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.